APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Indoleamine 2,3 Dioxygenase 1

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Indoleamine 2,3 Dioxygenase 1 Market Outlook and Growth Opportunities 2026

Report ID 174002450419 December 2025196 pages

Choose your research edition.

Industry ResearchIndoleamine 2,3 Dioxygenase 1 Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Indoleamine 2,3 Dioxygenase 1 Industry Growth and Trends Forecast to 2032107 pages · $3,450 USDMarket StructureGlobal Indoleamine 2,3 Dioxygenase 1 Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Indoleamine 2,3 Dioxygenase 1 Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Indoleamine 2,3 Dioxygenase 1 Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Indoleamine 2,3 Dioxygenase 1 market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Indoleamine 2,3 Dioxygenase 1 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Indoleamine 2,3 Dioxygenase 1 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Indoleamine 2,3 Dioxygenase 1 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Indoleamine 2,3 Dioxygenase 1 market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Indoleamine 2,3 Dioxygenase 1 market include F. Hoffmann-La Roche Ltd, Pfizer Inc, Bristol-Myers Squibb Company, Regen BioPharma Inc, Redx Pharma Plc, NewLink Genetics Corp, Netherlands Translational Research Center BV, Kyowa Hakko Kirin and IO Biotech ApS, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Indoleamine 2,3 Dioxygenase 1 market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Indoleamine 2,3 Dioxygenase 1 and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Indoleamine 2,3 Dioxygenase 1 sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Indoleamine 2,3 Dioxygenase 1 market size, projected growth trends, production technologies, key applications, and end-use industries.

Indoleamine 2,3 Dioxygenase 1 Segment by Company

F. Hoffmann-La Roche Ltd

Pfizer Inc

Bristol-Myers Squibb Company

Regen BioPharma Inc

Redx Pharma Plc

NewLink Genetics Corp

Netherlands Translational Research Center BV

Kyowa Hakko Kirin

IO Biotech ApS

Incyte Corp

Globavir Biosciences Inc

Genentech Inc

Ensemble Therapeutics Corp

BirchBioMed Inc

Indoleamine 2,3 Dioxygenase 1 Segment by Type

BMS-986205

Dcellvax

F-001287

Galanal

Epacadostat

Others

Indoleamine 2,3 Dioxygenase 1 Segment by Application

Gastric Cancer

Aolpecia

Glioma

Cervical Cancer

Others

Indoleamine 2,3 Dioxygenase 1 Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Indoleamine 2,3 Dioxygenase 1 status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Indoleamine 2,3 Dioxygenase 1 market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Indoleamine 2,3 Dioxygenase 1 significant trends, drivers, influence factors in global and regions.

6. To analyze Indoleamine 2,3 Dioxygenase 1 competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Indoleamine 2,3 Dioxygenase 1 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Indoleamine 2,3 Dioxygenase 1 and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Indoleamine 2,3 Dioxygenase 1.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Indoleamine 2,3 Dioxygenase 1 market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Indoleamine 2,3 Dioxygenase 1 industry.

Chapter 3: Detailed analysis of Indoleamine 2,3 Dioxygenase 1 manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Indoleamine 2,3 Dioxygenase 1 in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Indoleamine 2,3 Dioxygenase 1 in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Indoleamine 2,3 Dioxygenase 1 Industry Trends Table 2. Indoleamine 2,3 Dioxygenase 1 Industry Drivers Table 3. Indoleamine 2,3 Dioxygenase 1 Industry Opportunities and Challenges Table 4. Indoleamine 2,3 Dioxygenase 1 Industry Restraints Table 5. Global Indoleamine 2,3 Dioxygenase 1 Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Indoleamine 2,3 Dioxygenase 1 Revenue Share by Company (2021-2026) Table 7. Global Indoleamine 2,3 Dioxygenase 1 Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Indoleamine 2,3 Dioxygenase 1 Sales Volume Share by Company (2021-2026) Table 9. Global Indoleamine 2,3 Dioxygenase 1 Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Indoleamine 2,3 Dioxygenase 1 Company Ranking, (2024-2026) & (USD Million) Table 11. Global Indoleamine 2,3 Dioxygenase 1 Key Company Manufacturing Base & Headquarters Table 12. Global Indoleamine 2,3 Dioxygenase 1 Company, Product Type & Application Table 13. Global Indoleamine 2,3 Dioxygenase 1 Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Indoleamine 2,3 Dioxygenase 1 by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of BMS-986205 Table 18. Significant Companies of Dcellvax Table 19. Significant Companies of F-001287 Table 20. Significant Companies of Galanal Table 21. Significant Companies of Epacadostat Table 22. Significant Companies of Others Table 23. Global Indoleamine 2,3 Dioxygenase 1 Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Indoleamine 2,3 Dioxygenase 1 Sales Volume by Type (2021-2026) & (K Units) Table 25. Global Indoleamine 2,3 Dioxygenase 1 Sales Volume by Type (2027-2032) & (K Units) Table 26. Global Indoleamine 2,3 Dioxygenase 1 Sales Volume Share by Type (2021-2026) Table 27. Global Indoleamine 2,3 Dioxygenase 1 Sales Volume Share by Type (2027-2032) Table 28. Global Indoleamine 2,3 Dioxygenase 1 Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Indoleamine 2,3 Dioxygenase 1 Sales Value by Type (2021-2026) & (US$ Million) Table 30. Global Indoleamine 2,3 Dioxygenase 1 Sales Value by Type (2027-2032) & (US$ Million) Table 31. Global Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Type (2021-2026) Table 32. Global Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Type (2027-2032) Table 33. Significant Companies of Gastric Cancer Table 34. Significant Companies of Aolpecia Table 35. Significant Companies of Glioma Table 36. Significant Companies of Cervical Cancer Table 37. Significant Companies of Others Table 38. Global Indoleamine 2,3 Dioxygenase 1 Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 39. Global Indoleamine 2,3 Dioxygenase 1 Sales Volume by Application (2021-2026) & (K Units) Table 40. Global Indoleamine 2,3 Dioxygenase 1 Sales Volume by Application (2027-2032) & (K Units) Table 41. Global Indoleamine 2,3 Dioxygenase 1 Sales Volume Share by Application (2021-2026) Table 42. Global Indoleamine 2,3 Dioxygenase 1 Sales Volume Share by Application (2027-2032) Table 43. Global Indoleamine 2,3 Dioxygenase 1 Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 44. Global Indoleamine 2,3 Dioxygenase 1 Sales Value by Application (2021-2026) & (US$ Million) Table 45. Global Indoleamine 2,3 Dioxygenase 1 Sales Value by Application (2027-2032) & (US$ Million) Table 46. Global Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Application (2021-2026) Table 47. Global Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Application (2027-2032) Table 48. Global Indoleamine 2,3 Dioxygenase 1 Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 49. Global Indoleamine 2,3 Dioxygenase 1 Sales by Region (2021-2026) & (K Units) Table 50. Global Indoleamine 2,3 Dioxygenase 1 Sales Market Share by Region (2021-2026) Table 51. Global Indoleamine 2,3 Dioxygenase 1 Sales by Region (2027-2032) & (K Units) Table 52. Global Indoleamine 2,3 Dioxygenase 1 Sales Market Share by Region (2027-2032) Table 53. Global Indoleamine 2,3 Dioxygenase 1 Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 54. Global Indoleamine 2,3 Dioxygenase 1 Sales Value by Region (2021-2026) & (US$ Million) Table 55. Global Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Region (2021-2026) Table 56. Global Indoleamine 2,3 Dioxygenase 1 Sales Value by Region (2027-2032) & (US$ Million) Table 57. Global Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Region (2027-2032) Table 58. Global Indoleamine 2,3 Dioxygenase 1 Market Average Price (US$/Unit) by Region (2021-2026) Table 59. Global Indoleamine 2,3 Dioxygenase 1 Market Average Price (US$/Unit) by Region (2027-2032) Table 60. Global Indoleamine 2,3 Dioxygenase 1 Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 61. Global Indoleamine 2,3 Dioxygenase 1 Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Indoleamine 2,3 Dioxygenase 1 Sales by Country (2021-2026) & (K Units) Table 63. Global Indoleamine 2,3 Dioxygenase 1 Sales Market Share by Country (2021-2026) Table 64. Global Indoleamine 2,3 Dioxygenase 1 Sales by Country (2027-2032) & (K Units) Table 65. Global Indoleamine 2,3 Dioxygenase 1 Sales Market Share by Country (2027-2032) Table 66. Global Indoleamine 2,3 Dioxygenase 1 Sales Value by Country (2021-2026) & (US$ Million) Table 67. Global Indoleamine 2,3 Dioxygenase 1 Sales Value Market Share by Country (2021-2026) Table 68. Global Indoleamine 2,3 Dioxygenase 1 Sales Value by Country (2027-2032) & (US$ Million) Table 69. Global Indoleamine 2,3 Dioxygenase 1 Sales Value Market Share by Country (2027-2032) Table 70. F. Hoffmann-La Roche Ltd Company Information Table 71. F. Hoffmann-La Roche Ltd Business Overview Table 72. F. Hoffmann-La Roche Ltd Indoleamine 2,3 Dioxygenase 1 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. F. Hoffmann-La Roche Ltd Indoleamine 2,3 Dioxygenase 1 Product Portfolio Table 74. F. Hoffmann-La Roche Ltd Recent Development Table 75. Pfizer Inc Company Information Table 76. Pfizer Inc Business Overview Table 77. Pfizer Inc Indoleamine 2,3 Dioxygenase 1 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Pfizer Inc Indoleamine 2,3 Dioxygenase 1 Product Portfolio Table 79. Pfizer Inc Recent Development Table 80. Bristol-Myers Squibb Company Company Information Table 81. Bristol-Myers Squibb Company Business Overview Table 82. Bristol-Myers Squibb Company Indoleamine 2,3 Dioxygenase 1 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Bristol-Myers Squibb Company Indoleamine 2,3 Dioxygenase 1 Product Portfolio Table 84. Bristol-Myers Squibb Company Recent Development Table 85. Regen BioPharma Inc Company Information Table 86. Regen BioPharma Inc Business Overview Table 87. Regen BioPharma Inc Indoleamine 2,3 Dioxygenase 1 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Regen BioPharma Inc Indoleamine 2,3 Dioxygenase 1 Product Portfolio Table 89. Regen BioPharma Inc Recent Development Table 90. Redx Pharma Plc Company Information Table 91. Redx Pharma Plc Business Overview Table 92. Redx Pharma Plc Indoleamine 2,3 Dioxygenase 1 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Redx Pharma Plc Indoleamine 2,3 Dioxygenase 1 Product Portfolio Table 94. Redx Pharma Plc Recent Development Table 95. NewLink Genetics Corp Company Information Table 96. NewLink Genetics Corp Business Overview Table 97. NewLink Genetics Corp Indoleamine 2,3 Dioxygenase 1 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. NewLink Genetics Corp Indoleamine 2,3 Dioxygenase 1 Product Portfolio Table 99. NewLink Genetics Corp Recent Development Table 100. Netherlands Translational Research Center BV Company Information Table 101. Netherlands Translational Research Center BV Business Overview Table 102. Netherlands Translational Research Center BV Indoleamine 2,3 Dioxygenase 1 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Netherlands Translational Research Center BV Indoleamine 2,3 Dioxygenase 1 Product Portfolio Table 104. Netherlands Translational Research Center BV Recent Development Table 105. Kyowa Hakko Kirin Company Information Table 106. Kyowa Hakko Kirin Business Overview Table 107. Kyowa Hakko Kirin Indoleamine 2,3 Dioxygenase 1 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Kyowa Hakko Kirin Indoleamine 2,3 Dioxygenase 1 Product Portfolio Table 109. Kyowa Hakko Kirin Recent Development Table 110. IO Biotech ApS Company Information Table 111. IO Biotech ApS Business Overview Table 112. IO Biotech ApS Indoleamine 2,3 Dioxygenase 1 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. IO Biotech ApS Indoleamine 2,3 Dioxygenase 1 Product Portfolio Table 114. IO Biotech ApS Recent Development Table 115. Incyte Corp Company Information Table 116. Incyte Corp Business Overview Table 117. Incyte Corp Indoleamine 2,3 Dioxygenase 1 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. Incyte Corp Indoleamine 2,3 Dioxygenase 1 Product Portfolio Table 119. Incyte Corp Recent Development Table 120. Globavir Biosciences Inc Company Information Table 121. Globavir Biosciences Inc Business Overview Table 122. Globavir Biosciences Inc Indoleamine 2,3 Dioxygenase 1 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. Globavir Biosciences Inc Indoleamine 2,3 Dioxygenase 1 Product Portfolio Table 124. Globavir Biosciences Inc Recent Development Table 125. Genentech Inc Company Information Table 126. Genentech Inc Business Overview Table 127. Genentech Inc Indoleamine 2,3 Dioxygenase 1 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 128. Genentech Inc Indoleamine 2,3 Dioxygenase 1 Product Portfolio Table 129. Genentech Inc Recent Development Table 130. Ensemble Therapeutics Corp Company Information Table 131. Ensemble Therapeutics Corp Business Overview Table 132. Ensemble Therapeutics Corp Indoleamine 2,3 Dioxygenase 1 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 133. Ensemble Therapeutics Corp Indoleamine 2,3 Dioxygenase 1 Product Portfolio Table 134. Ensemble Therapeutics Corp Recent Development Table 135. BirchBioMed Inc Company Information Table 136. BirchBioMed Inc Business Overview Table 137. BirchBioMed Inc Indoleamine 2,3 Dioxygenase 1 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 138. BirchBioMed Inc Indoleamine 2,3 Dioxygenase 1 Product Portfolio Table 139. BirchBioMed Inc Recent Development Table 140. Key Raw Materials Table 141. Raw Materials Key Suppliers Table 142. Indoleamine 2,3 Dioxygenase 1 Distributors List Table 143. Indoleamine 2,3 Dioxygenase 1 Customers List Table 144. Research Programs/Design for This Report Table 145. Authors List of This Report Table 146. Secondary Sources Table 147. Primary Sources List of Figures Figure 1. Indoleamine 2,3 Dioxygenase 1 Product Image Figure 2. Global Indoleamine 2,3 Dioxygenase 1 Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Indoleamine 2,3 Dioxygenase 1 Sales Value (2021-2032) & (US$ Million) Figure 4. Global Indoleamine 2,3 Dioxygenase 1 Sales (2021-2032) & (K Units) Figure 5. Global Indoleamine 2,3 Dioxygenase 1 Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Indoleamine 2,3 Dioxygenase 1 Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. BMS-986205 Image Figure 10. Dcellvax Image Figure 11. F-001287 Image Figure 12. Galanal Image Figure 13. Epacadostat Image Figure 14. Others Image Figure 15. Global Indoleamine 2,3 Dioxygenase 1 Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global Indoleamine 2,3 Dioxygenase 1 Sales Volume Share 2021 VS 2025 VS 2032 Figure 17. Global Indoleamine 2,3 Dioxygenase 1 Sales Volume Share by Type (2021-2032) Figure 18. Global Indoleamine 2,3 Dioxygenase 1 Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Indoleamine 2,3 Dioxygenase 1 Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Type (2021-2032) Figure 21. Gastric Cancer Image Figure 22. Aolpecia Image Figure 23. Glioma Image Figure 24. Cervical Cancer Image Figure 25. Others Image Figure 26. Global Indoleamine 2,3 Dioxygenase 1 Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 27. Global Indoleamine 2,3 Dioxygenase 1 Sales Volume Share 2021 VS 2025 VS 2032 Figure 28. Global Indoleamine 2,3 Dioxygenase 1 Sales Volume Share by Application (2021-2032) Figure 29. Global Indoleamine 2,3 Dioxygenase 1 Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 30. Global Indoleamine 2,3 Dioxygenase 1 Sales Value Share 2021 VS 2025 VS 2032 Figure 31. Global Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Application (2021-2032) Figure 32. Global Indoleamine 2,3 Dioxygenase 1 Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 33. Global Indoleamine 2,3 Dioxygenase 1 Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 34. Global Indoleamine 2,3 Dioxygenase 1 Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 35. Global Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 36. North America Indoleamine 2,3 Dioxygenase 1 Sales Value (2021-2032) & (US$ Million) Figure 37. North America Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Europe Indoleamine 2,3 Dioxygenase 1 Sales Value (2021-2032) & (US$ Million) Figure 39. Europe Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Asia-Pacific Indoleamine 2,3 Dioxygenase 1 Sales Value (2021-2032) & (US$ Million) Figure 41. Asia-Pacific Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Country (%), 2025 VS 2032 Figure 42. South America Indoleamine 2,3 Dioxygenase 1 Sales Value (2021-2032) & (US$ Million) Figure 43. South America Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Country (%), 2025 VS 2032 Figure 44. Middle East & Africa Indoleamine 2,3 Dioxygenase 1 Sales Value (2021-2032) & (US$ Million) Figure 45. Middle East & Africa Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Country (%), 2025 VS 2032 Figure 46. USA Indoleamine 2,3 Dioxygenase 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. USA Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. USA Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Canada Indoleamine 2,3 Dioxygenase 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Canada Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Canada Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Mexico Indoleamine 2,3 Dioxygenase 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Mexico Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Mexico Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Germany Indoleamine 2,3 Dioxygenase 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Germany Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Germany Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. France Indoleamine 2,3 Dioxygenase 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. France Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. France Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. U.K. Indoleamine 2,3 Dioxygenase 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. U.K. Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. U.K. Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Italy Indoleamine 2,3 Dioxygenase 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Italy Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Italy Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Spain Indoleamine 2,3 Dioxygenase 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Spain Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Spain Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Russia Indoleamine 2,3 Dioxygenase 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Russia Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Russia Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Netherlands Indoleamine 2,3 Dioxygenase 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Netherlands Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Netherlands Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Nordic Countries Indoleamine 2,3 Dioxygenase 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Nordic Countries Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Nordic Countries Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. China Indoleamine 2,3 Dioxygenase 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. China Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. China Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Japan Indoleamine 2,3 Dioxygenase 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Japan Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Japan Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. South Korea Indoleamine 2,3 Dioxygenase 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. South Korea Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. South Korea Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. India Indoleamine 2,3 Dioxygenase 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. India Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. India Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Australia Indoleamine 2,3 Dioxygenase 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Australia Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Australia Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Southeast Asia Indoleamine 2,3 Dioxygenase 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Southeast Asia Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Southeast Asia Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Brazil Indoleamine 2,3 Dioxygenase 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Brazil Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Brazil Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Argentina Indoleamine 2,3 Dioxygenase 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Argentina Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Argentina Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Chile Indoleamine 2,3 Dioxygenase 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Chile Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Chile Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Colombia Indoleamine 2,3 Dioxygenase 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Colombia Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Colombia Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Peru Indoleamine 2,3 Dioxygenase 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Peru Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Peru Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Saudi Arabia Indoleamine 2,3 Dioxygenase 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Saudi Arabia Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Saudi Arabia Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Israel Indoleamine 2,3 Dioxygenase 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Israel Arabia Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Israel Arabia Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. UAE Indoleamine 2,3 Dioxygenase 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. UAE Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. UAE Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Turkey Indoleamine 2,3 Dioxygenase 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Turkey Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Turkey Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Iran Indoleamine 2,3 Dioxygenase 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Iran Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Iran Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Egypt Indoleamine 2,3 Dioxygenase 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 128. Egypt Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 129. Egypt Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 130. Indoleamine 2,3 Dioxygenase 1 Value Chain Figure 131. Manufacturing Cost Structure Figure 132. Indoleamine 2,3 Dioxygenase 1 Sales Mode & Process Figure 133. Direct Comparison with Distribution Share Figure 134. Distributors Profiles Figure 135. Years Considered Figure 136. Research Process Figure 137. Key Executives Interviewed

Scope & coverage.

Types
  • BMS-986205
  • Dcellvax
  • F-001287
  • Galanal
  • Epacadostat
  • Others
Applications
  • Gastric Cancer
  • Aolpecia
  • Glioma
  • Cervical Cancer
  • Others
Companies covered
  • F. Hoffmann-La Roche Ltd
  • Pfizer Inc
  • Bristol-Myers Squibb Company
  • Regen BioPharma Inc
  • Redx Pharma Plc
  • NewLink Genetics Corp
  • Netherlands Translational Research Center BV
  • Kyowa Hakko Kirin
  • IO Biotech ApS
  • Incyte Corp
  • Globavir Biosciences Inc
  • Genentech Inc
  • Ensemble Therapeutics Corp
  • BirchBioMed Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Indoleamine 2,3 Dioxygenase 1 Sales Value (2021-2032)
  4. 1.2.2 Global Indoleamine 2,3 Dioxygenase 1 Sales Volume (2021-2032)
  5. 1.2.3 Global Indoleamine 2,3 Dioxygenase 1 Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Indoleamine 2,3 Dioxygenase 1 Market Dynamics
  1. 2.1 Indoleamine 2,3 Dioxygenase 1 Industry Trends
  2. 2.2 Indoleamine 2,3 Dioxygenase 1 Industry Drivers
  3. 2.3 Indoleamine 2,3 Dioxygenase 1 Industry Opportunities and Challenges
  4. 2.4 Indoleamine 2,3 Dioxygenase 1 Industry Restraints
3 Indoleamine 2,3 Dioxygenase 1 Market by Company
  1. 3.1 Global Indoleamine 2,3 Dioxygenase 1 Company Revenue Ranking in 2025
  2. 3.2 Global Indoleamine 2,3 Dioxygenase 1 Revenue by Company (2021-2026)
  3. 3.3 Global Indoleamine 2,3 Dioxygenase 1 Sales Volume by Company (2021-2026)
  4. 3.4 Global Indoleamine 2,3 Dioxygenase 1 Average Price by Company (2021-2026)
  5. 3.5 Global Indoleamine 2,3 Dioxygenase 1 Company Ranking (2024-2026)
  6. 3.6 Global Indoleamine 2,3 Dioxygenase 1 Company Manufacturing Base and Headquarters
  7. 3.7 Global Indoleamine 2,3 Dioxygenase 1 Company Product Type and Application
  8. 3.8 Global Indoleamine 2,3 Dioxygenase 1 Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Indoleamine 2,3 Dioxygenase 1 Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Indoleamine 2,3 Dioxygenase 1 Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Indoleamine 2,3 Dioxygenase 1 Market by Type
  1. 4.1 Indoleamine 2,3 Dioxygenase 1 Type Introduction
  2. 4.1.1 BMS-986205
  3. 4.1.2 Dcellvax
  4. 4.1.3 F-001287
  5. 4.1.4 Galanal
  6. 4.1.5 Epacadostat
  7. 4.1.6 Others
  8. 4.2 Global Indoleamine 2,3 Dioxygenase 1 Sales Volume by Type
  9. 4.2.1 Global Indoleamine 2,3 Dioxygenase 1 Sales Volume by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Indoleamine 2,3 Dioxygenase 1 Sales Volume by Type (2021-2032)
  11. 4.2.3 Global Indoleamine 2,3 Dioxygenase 1 Sales Volume Share by Type (2021-2032)
  12. 4.3 Global Indoleamine 2,3 Dioxygenase 1 Sales Value by Type
  13. 4.3.1 Global Indoleamine 2,3 Dioxygenase 1 Sales Value by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Indoleamine 2,3 Dioxygenase 1 Sales Value by Type (2021-2032)
  15. 4.3.3 Global Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Type (2021-2032)
5 Indoleamine 2,3 Dioxygenase 1 Market by Application
  1. 5.1 Indoleamine 2,3 Dioxygenase 1 Application Introduction
  2. 5.1.1 Gastric Cancer
  3. 5.1.2 Aolpecia
  4. 5.1.3 Glioma
  5. 5.1.4 Cervical Cancer
  6. 5.1.5 Others
  7. 5.2 Global Indoleamine 2,3 Dioxygenase 1 Sales Volume by Application
  8. 5.2.1 Global Indoleamine 2,3 Dioxygenase 1 Sales Volume by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Indoleamine 2,3 Dioxygenase 1 Sales Volume by Application (2021-2032)
  10. 5.2.3 Global Indoleamine 2,3 Dioxygenase 1 Sales Volume Share by Application (2021-2032)
  11. 5.3 Global Indoleamine 2,3 Dioxygenase 1 Sales Value by Application
  12. 5.3.1 Global Indoleamine 2,3 Dioxygenase 1 Sales Value by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Indoleamine 2,3 Dioxygenase 1 Sales Value by Application (2021-2032)
  14. 5.3.3 Global Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Application (2021-2032)
6 Indoleamine 2,3 Dioxygenase 1 Regional Sales and Value Analysis
  1. 6.1 Global Indoleamine 2,3 Dioxygenase 1 Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Indoleamine 2,3 Dioxygenase 1 Sales by Region (2021-2032)
  3. 6.2.1 Global Indoleamine 2,3 Dioxygenase 1 Sales by Region: 2021-2026
  4. 6.2.2 Global Indoleamine 2,3 Dioxygenase 1 Sales by Region (2027-2032)
  5. 6.3 Global Indoleamine 2,3 Dioxygenase 1 Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Indoleamine 2,3 Dioxygenase 1 Sales Value by Region (2021-2032)
  7. 6.4.1 Global Indoleamine 2,3 Dioxygenase 1 Sales Value by Region: 2021-2026
  8. 6.4.2 Global Indoleamine 2,3 Dioxygenase 1 Sales Value by Region (2027-2032)
  9. 6.5 Global Indoleamine 2,3 Dioxygenase 1 Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Indoleamine 2,3 Dioxygenase 1 Sales Value (2021-2032)
  12. 6.6.2 North America Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Indoleamine 2,3 Dioxygenase 1 Sales Value (2021-2032)
  15. 6.7.2 Europe Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Indoleamine 2,3 Dioxygenase 1 Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Indoleamine 2,3 Dioxygenase 1 Sales Value (2021-2032)
  21. 6.9.2 South America Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Indoleamine 2,3 Dioxygenase 1 Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Country, 2025 VS 2032
7 Indoleamine 2,3 Dioxygenase 1 Country-level Sales and Value Analysis
  1. 7.1 Global Indoleamine 2,3 Dioxygenase 1 Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Indoleamine 2,3 Dioxygenase 1 Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Indoleamine 2,3 Dioxygenase 1 Sales by Country (2021-2032)
  4. 7.3.1 Global Indoleamine 2,3 Dioxygenase 1 Sales by Country (2021-2026)
  5. 7.3.2 Global Indoleamine 2,3 Dioxygenase 1 Sales by Country (2027-2032)
  6. 7.4 Global Indoleamine 2,3 Dioxygenase 1 Sales Value by Country (2021-2032)
  7. 7.4.1 Global Indoleamine 2,3 Dioxygenase 1 Sales Value by Country (2021-2026)
  8. 7.4.2 Global Indoleamine 2,3 Dioxygenase 1 Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Indoleamine 2,3 Dioxygenase 1 Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Indoleamine 2,3 Dioxygenase 1 Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Indoleamine 2,3 Dioxygenase 1 Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Indoleamine 2,3 Dioxygenase 1 Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Indoleamine 2,3 Dioxygenase 1 Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Indoleamine 2,3 Dioxygenase 1 Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Indoleamine 2,3 Dioxygenase 1 Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Indoleamine 2,3 Dioxygenase 1 Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Indoleamine 2,3 Dioxygenase 1 Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Indoleamine 2,3 Dioxygenase 1 Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Indoleamine 2,3 Dioxygenase 1 Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Indoleamine 2,3 Dioxygenase 1 Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Indoleamine 2,3 Dioxygenase 1 Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Indoleamine 2,3 Dioxygenase 1 Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Indoleamine 2,3 Dioxygenase 1 Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Indoleamine 2,3 Dioxygenase 1 Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Indoleamine 2,3 Dioxygenase 1 Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Indoleamine 2,3 Dioxygenase 1 Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Indoleamine 2,3 Dioxygenase 1 Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Indoleamine 2,3 Dioxygenase 1 Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Indoleamine 2,3 Dioxygenase 1 Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Indoleamine 2,3 Dioxygenase 1 Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Indoleamine 2,3 Dioxygenase 1 Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Indoleamine 2,3 Dioxygenase 1 Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Indoleamine 2,3 Dioxygenase 1 Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Indoleamine 2,3 Dioxygenase 1 Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Indoleamine 2,3 Dioxygenase 1 Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Indoleamine 2,3 Dioxygenase 1 Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Indoleamine 2,3 Dioxygenase 1 Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 F. Hoffmann-La Roche Ltd
  2. 8.1.1 F. Hoffmann-La Roche Ltd Company Information
  3. 8.1.2 F. Hoffmann-La Roche Ltd Business Overview
  4. 8.1.3 F. Hoffmann-La Roche Ltd Indoleamine 2,3 Dioxygenase 1 Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 F. Hoffmann-La Roche Ltd Indoleamine 2,3 Dioxygenase 1 Product Portfolio
  6. 8.1.5 F. Hoffmann-La Roche Ltd Recent Developments
  7. 8.2 Pfizer Inc
  8. 8.2.1 Pfizer Inc Company Information
  9. 8.2.2 Pfizer Inc Business Overview
  10. 8.2.3 Pfizer Inc Indoleamine 2,3 Dioxygenase 1 Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Pfizer Inc Indoleamine 2,3 Dioxygenase 1 Product Portfolio
  12. 8.2.5 Pfizer Inc Recent Developments
  13. 8.3 Bristol-Myers Squibb Company
  14. 8.3.1 Bristol-Myers Squibb Company Company Information
  15. 8.3.2 Bristol-Myers Squibb Company Business Overview
  16. 8.3.3 Bristol-Myers Squibb Company Indoleamine 2,3 Dioxygenase 1 Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Bristol-Myers Squibb Company Indoleamine 2,3 Dioxygenase 1 Product Portfolio
  18. 8.3.5 Bristol-Myers Squibb Company Recent Developments
  19. 8.4 Regen BioPharma Inc
  20. 8.4.1 Regen BioPharma Inc Company Information
  21. 8.4.2 Regen BioPharma Inc Business Overview
  22. 8.4.3 Regen BioPharma Inc Indoleamine 2,3 Dioxygenase 1 Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Regen BioPharma Inc Indoleamine 2,3 Dioxygenase 1 Product Portfolio
  24. 8.4.5 Regen BioPharma Inc Recent Developments
  25. 8.5 Redx Pharma Plc
  26. 8.5.1 Redx Pharma Plc Company Information
  27. 8.5.2 Redx Pharma Plc Business Overview
  28. 8.5.3 Redx Pharma Plc Indoleamine 2,3 Dioxygenase 1 Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Redx Pharma Plc Indoleamine 2,3 Dioxygenase 1 Product Portfolio
  30. 8.5.5 Redx Pharma Plc Recent Developments
  31. 8.6 NewLink Genetics Corp
  32. 8.6.1 NewLink Genetics Corp Company Information
  33. 8.6.2 NewLink Genetics Corp Business Overview
  34. 8.6.3 NewLink Genetics Corp Indoleamine 2,3 Dioxygenase 1 Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 NewLink Genetics Corp Indoleamine 2,3 Dioxygenase 1 Product Portfolio
  36. 8.6.5 NewLink Genetics Corp Recent Developments
  37. 8.7 Netherlands Translational Research Center BV
  38. 8.7.1 Netherlands Translational Research Center BV Company Information
  39. 8.7.2 Netherlands Translational Research Center BV Business Overview
  40. 8.7.3 Netherlands Translational Research Center BV Indoleamine 2,3 Dioxygenase 1 Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Netherlands Translational Research Center BV Indoleamine 2,3 Dioxygenase 1 Product Portfolio
  42. 8.7.5 Netherlands Translational Research Center BV Recent Developments
  43. 8.8 Kyowa Hakko Kirin
  44. 8.8.1 Kyowa Hakko Kirin Company Information
  45. 8.8.2 Kyowa Hakko Kirin Business Overview
  46. 8.8.3 Kyowa Hakko Kirin Indoleamine 2,3 Dioxygenase 1 Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Kyowa Hakko Kirin Indoleamine 2,3 Dioxygenase 1 Product Portfolio
  48. 8.8.5 Kyowa Hakko Kirin Recent Developments
  49. 8.9 IO Biotech ApS
  50. 8.9.1 IO Biotech ApS Company Information
  51. 8.9.2 IO Biotech ApS Business Overview
  52. 8.9.3 IO Biotech ApS Indoleamine 2,3 Dioxygenase 1 Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 IO Biotech ApS Indoleamine 2,3 Dioxygenase 1 Product Portfolio
  54. 8.9.5 IO Biotech ApS Recent Developments
  55. 8.10 Incyte Corp
  56. 8.10.1 Incyte Corp Company Information
  57. 8.10.2 Incyte Corp Business Overview
  58. 8.10.3 Incyte Corp Indoleamine 2,3 Dioxygenase 1 Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Incyte Corp Indoleamine 2,3 Dioxygenase 1 Product Portfolio
  60. 8.10.5 Incyte Corp Recent Developments
  61. 8.11 Globavir Biosciences Inc
  62. 8.11.1 Globavir Biosciences Inc Company Information
  63. 8.11.2 Globavir Biosciences Inc Business Overview
  64. 8.11.3 Globavir Biosciences Inc Indoleamine 2,3 Dioxygenase 1 Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Globavir Biosciences Inc Indoleamine 2,3 Dioxygenase 1 Product Portfolio
  66. 8.11.5 Globavir Biosciences Inc Recent Developments
  67. 8.12 Genentech Inc
  68. 8.12.1 Genentech Inc Company Information
  69. 8.12.2 Genentech Inc Business Overview
  70. 8.12.3 Genentech Inc Indoleamine 2,3 Dioxygenase 1 Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Genentech Inc Indoleamine 2,3 Dioxygenase 1 Product Portfolio
  72. 8.12.5 Genentech Inc Recent Developments
  73. 8.13 Ensemble Therapeutics Corp
  74. 8.13.1 Ensemble Therapeutics Corp Company Information
  75. 8.13.2 Ensemble Therapeutics Corp Business Overview
  76. 8.13.3 Ensemble Therapeutics Corp Indoleamine 2,3 Dioxygenase 1 Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Ensemble Therapeutics Corp Indoleamine 2,3 Dioxygenase 1 Product Portfolio
  78. 8.13.5 Ensemble Therapeutics Corp Recent Developments
  79. 8.14 BirchBioMed Inc
  80. 8.14.1 BirchBioMed Inc Company Information
  81. 8.14.2 BirchBioMed Inc Business Overview
  82. 8.14.3 BirchBioMed Inc Indoleamine 2,3 Dioxygenase 1 Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 BirchBioMed Inc Indoleamine 2,3 Dioxygenase 1 Product Portfolio
  84. 8.14.5 BirchBioMed Inc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Indoleamine 2,3 Dioxygenase 1 Value Chain Analysis
  2. 9.1.1 Indoleamine 2,3 Dioxygenase 1 Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Indoleamine 2,3 Dioxygenase 1 Sales Mode & Process
  6. 9.2 Indoleamine 2,3 Dioxygenase 1 Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Indoleamine 2,3 Dioxygenase 1 Distributors
  9. 9.2.3 Indoleamine 2,3 Dioxygenase 1 Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst